Skip to main content
OpenTrials
Completed

NCT Number: NCT05095129

The Role of Genetic Factors in the Development of Idiopathic Scoliosis in the Kazakh Population

The purpose of this study is to identify genetic determinants of susceptibility to idiopathic scoliosis . It will assist in predicting individual risks of disease progression and would help to clarify pathophysiologic mechanisms of idiopathic scoliosis

Completed

Looking for future studies?

Notify Me

Key information

Age range

4 year–40 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Scientific center of traumatology and orthopedics named after academician Batpenova ND

Almaty, Kazakhstan

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Persons with a doctor-confirmed diagnosis of idiopathic scoliosis;
  • Persons of Kazakh nationality, whose paternal and maternal grandparents are Kazakhs;
  • Hereditary history of scoliosis;
  • Persons who are able and willing to provide written informed consent;

Exclusion criteria

  • Patients diagnosed with idiopathic scoliosis under 4 and over 40 years of age;
  • Representatives of the Kazakh ethnic group less than 3 generations;
  • No family history of bilateral idiopathic scoliosis;
  • Patients with an acute period of the inflammatory process (laboratory and clinical signs);
  • Persons who, in the opinion of the researcher, are mentally or legally incapacitated, which prevents obtaining informed consent;
  • Pregnant or lactating women;
  • Tuberculosis of any localization in the active phase and in history;
  • Severe and decompensated diseases of the liver and kidneys, cardiovascular system;
  • Severe and decompensated course of endocrine diseases;
  • Autoimmune diseases;
  • Systemic diseases;
  • Oncological diseases;

Treatment and study plan

SNP analysis of the DNA

Genetic

SNP analysis of the DNA obtained from peripheral blood sample

Primary outcomes

  1. Genotyping for the SNP associated with liver cirrhosis

    Time frame: 1 year

    Genotype frequency of SNP in the study genes of participants and control participants.

Sponsors and collaborators

Lead sponsor

Asfendiyarov Kazakh National Medical University

Other

Registry information

Official study title

Preventive and Personalized Medicine (2021-2023)

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Oct 27, 2021
Registry last updated
Mar 14, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.